2022 Venom Evolution, Function and Biomedical Applications GRC/GRS

2022 毒液进化、功能和生物医学应用 GRC/GRS

• 批准号: 10391650
• 负责人: Mande N. Holford
• 金额: $ 3万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-12-01 至 2022-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10391650
• 关键词: Address; Animals; Anticoagulation; Applied Research; Area; Basic Science; Biological Models; Biology; Biomedical Research; Biotechnology; Breathing; Captopril; Categories; Collaborations; Communication; Communities; Complex; Coronary; Coupled; Development; Diabetes Mellitus; Discipline; Ecology; Economics; Epilepsy; Evolution; Fostering; Future; Gender; General Population; Genomics; Goals; Health; Human; Human Pathology; Hypertension; Iceberg; Impairment; Industry; Ion Channel; Ion Channel Gating; Knowledge; Life; Ligands; Link; Manuscripts; Medicine; Methodology; Molecular; Molecular Structure; Molecular Target; National Center for Complementary and Integrative Health; Natural Sciences; Outcome; Pain; Pain management; Participant; Peptides; Pharmaceutical Preparations; Pharmacology; Physiological; Postdoctoral Fellow; Predatory Behavior; Prevention strategy; Protein Engineering; Proteomics; Publications; Research; Route; Science; Scientist; Societies; Source; Study models; Syndrome; Targeted Toxins; Technology; Therapeutic; Time; Toxin; Translating; Trees; Venoms; World Health Organization; bivalirudin; cohesion; drug development; drug discovery; early-career faculty; economic impact; eptifibatide; exenatide; frontier; global health; graduate student; health economics; human disease; innovation; interdisciplinary approach; meetings; neglected tropical diseases; non-opioid analgesic; novel; novel therapeutics; programs; receptor; research and development; response; socioeconomics; symposium; therapeutic development; tirofiban; tool; translational applications; voltage; ziconotide; Address; Animals; Anticoagulation; Applied Research; Area; Basic Science; Biological Models; Biology; Biomedical Research; Biotechnology; Breathing; Captopril; Categories; Collaborations; Communication; Communities; Complex; Coronary; Coupled; Development; Diabetes Mellitus; Discipline; Ecology; Economics; Epilepsy; Evolution; Fostering; Future; Gender; General Population; Genomics; Goals; Health; Human; Human Pathology; Hypertension; Iceberg; Impairment; Industry; Ion Channel; Ion Channel Gating; Knowledge; Life; Ligands; Link; Manuscripts; Medicine; Methodology; Molecular; Molecular Structure; Molecular Target; National Center for Complementary and Integrative Health; Natural Sciences; Outcome; Pain; Pain management; Participant; Peptides; Pharmaceutical Preparations; Pharmacology; Physiological; Postdoctoral Fellow; Predatory Behavior; Prevention strategy; Protein Engineering; Proteomics; Publications; Research; Route; Science; Scientist; Societies; Source; Study models; Syndrome; Targeted Toxins; Technology; Therapeutic; Time; Toxin; Translating; Trees; Venoms; World Health Organization; bivalirudin; cohesion; drug development; drug discovery; early-career faculty; economic impact; eptifibatide; exenatide; frontier; global health; graduate student; health economics; human disease; innovation; interdisciplinary approach; meetings; neglected tropical diseases; non-opioid analgesic; novel; novel therapeutics; programs; receptor; research and development; response; socioeconomics; symposium; therapeutic development; tirofiban; tool; translational applications; voltage; ziconotide

Summary/Abstract Animal venoms are among the most complex natural secretions known, comprising a mixture of bioactive compounds often referred to as toxins. Despite their complexity, the molecular structure and targets of toxins, which include receptors and voltage- and ligand-gated ion channels, are relatively conserved throughout the animal kingdom. These features make venom an extremely successful evolutionary innovation whose components are ideal candidates for discovery and development of therapeutics to treat a wide range of human pathologies. Currently, six venom-derived peptides are commercially available drugs: ziconotide for pain; exenatide for diabetes; bivalirudin for anticoagulation; captopril for hypertension; and eptifibatide and tirofiban for coronary syndrome. Venom research is growing exponentially, as evidenced by the increase in venom publications, symposia, biomedical applications and biotech startup companies, leading to important socio- economic impacts on society. As a consequence, the World Economic Forum recently designated Venomics as one of the four most promising frontiers of science, and the World Health Organization classified snakebite as a “Category A Neglected Tropical Disease” and launched a global strategy for prevention and control of snakebite envenoming. Yet, the full potential of venom remains untapped due to a lack of knowledge on many venomous animals and a scarcity of opportunities to create a cohesive research community focused on the diversity of venom. Venom occurs so broadly across the animal tree of life that no single conference links experts in the basic and applied sciences of venomous animals to those investigating the physiological and pharmacological applications of venom. The 2022 Gordon Research Conference and Seminar on Venom Evolution, Function and Biomedical Applications (Venoms-GRC/GRS) aims to overcome these hurdles by coalescing an interdisciplinary group of academic and industry professionals to address venom as both a global health problem and a route to innovation in health solutions, including alternative, non-opioid pain management strategies. Our goals are to evaluate needs and challenges pertaining to drug discovery and development, identify future goals for venom research that will enable the field to grow and impact biomedical research and drug development and, via a special issue of manuscripts from collaborations fostered at the conference, disseminate innovative future directions in the venom field. The conference chairs are making significant efforts to invite a culturally, ethnically, and gender diverse group of 150 established and early-career faculty, postdoctoral fellows, and graduate students to the 2022 Venoms-GRC/GRS. Our program will foster a community of experts focused on complementary and integrative topics in venom drug discovery and development – key issues that are relevant to NCCIH.

摘要/摘要 动物毒液是已知的最复杂的自然分泌物之一，完成了生物活性的混合物 化合物通常称为毒素。尽管它们的复杂性，毒素的分子结构和靶标的 包括受体以及电压和配体门控离子通道，相对构成 动物王国。这些功能使毒液成为非常成功的进化创新 组件是发现和开发治疗剂的理想候选者，以治疗广泛的人类 病理。目前，有六个毒液衍生的宠物是市售药物：Ziconotide son疼痛； 糖尿病的艾鉴定；双伏丁素用于抗凝；卡托普利用于高血压；和eptibibatide和tirofiban 用于冠状动脉综合征。毒液研究正在成倍增长，毒液的增加证明了 出版物，研讨会，生物医学应用和生物技术初创公司，导致重要的社会 经济对社会的影响。结果，世界经济论坛最近将毒物学指定为 科学的四个最有前途的前沿之一，世界卫生组织将蛇列为 “被忽视的热带疾病类别”，并启动了预防和控制的全球战略 蛇咬伤。然而，由于许多人缺乏知识，毒液的全部潜力仍未开发 有毒动物和稀缺的机会创建一个凝聚力的研究社区，重点是 毒液的多样性。毒液在生命的动物树上如此广泛，以至于没有单一的会议链接专家 在研究生理学和 毒液的药理应用。 2022年戈登研究会议和毒液研讨会 进化，功能和生物医学应用（Venoms-GRC/GRS）旨在克服这些障碍 融合一个学术和行业专业人员的跨学科小组，将毒液作为全球 健康问题和健康解决方案的创新途径，包括替代性，非阿片类疼痛管理 策略。我们的目标是评估与药物发现和开发有关的需求和挑战， 确定毒液研究的未来目标，这将使该领域能够成长并影响生物医学研究和 药物开发以及通过在会议上培养的合作的手稿的特刊， 在毒液领域传播创新的未来方向。会议椅正在付出巨大的努力 为了邀请150个成立和早期职业的文化，种族和性别多样化的群体， 博士后研究员和研究生到2022 DENOMS-GRC/GRS。我们的计划将促进 专家社区的重点是毒药发现和综合主题 开发 - 与NCCIH相关的关键问题。